Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
about
Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ RegimenMyeloid cell signatures in tumor microenvironment predicts therapeutic response in cancerThe interaction of anticancer therapies with tumor-associated macrophagesTumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization.Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytesTumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growthMacrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Macrophage depletion reduces postsurgical tumor recurrence and metastatic growth in a spontaneous murine model of melanoma.Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).Hypoxia induces macrophage polarization and re-education toward an M2 phenotype in U87 and U251 glioblastoma modelsDual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.The role of microglia and macrophages in glioma maintenance and progressionSoluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas.Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancerSDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma.M2-like tumor-associated macrophages drive vasculogenic mimicry through amplification of IL-6 expression in glioma cells.Current status of antiangiogenic therapies for glioblastomas.Reciprocal Supportive Interplay between Glioblastoma and Tumor-Associated Macrophages.Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.Antiangiogenic therapies for glioblastoma.Myeloid Derived Suppressor Cells: Fuel the Fire.The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.Tumor-associated macrophages and anti-tumor therapies: complex links.CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma.The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.A comprehensive profile of recurrent glioblastoma.Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.New Directions in Anti-Angiogenic Therapy for Glioblastoma.The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.The Microenvironmental Landscape of Brain Tumors.Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.The immunological function of GABAergic system.Type 1 Immune Mechanisms Driven by the Response to Infection with Attenuated Rabies Virus Result in Changes in the Immune Bias of the Tumor Microenvironment and Necrosis of Mouse GL261 Brain Tumors.Transcription Factor NFAT5 Promotes Glioblastoma Cell-driven Angiogenesis via SBF2-AS1/miR-338-3p-Mediated EGFL7 Expression Change.
P2860
Q26749972-5DDD3F82-4D50-45E3-8962-657EDB6BDC7AQ26752838-DAE8192F-4FC1-46E9-B913-A082658C9895Q27016634-C1F49889-4191-4684-BB8E-3A9E2FF1A2FBQ30583140-D0291454-821A-47AD-BF3F-6D2BFB0453B2Q33688579-A59ADFF5-E8C2-4077-BD9B-9A884494CE98Q33770873-649F8716-B314-4CF7-BFAC-5DC8E7B4D828Q33853991-D117B16B-AEE5-4711-ADCA-ADE89591A479Q34293163-BFE7EF9D-86B2-4273-87D9-595BCE561739Q35895174-BEAC3D44-C2AB-48A1-8661-21AD53D30008Q36356092-58264F3C-9B9F-479D-9137-2F5BE6410CB2Q36390700-D1507075-823F-47BE-96C1-D3CDAE2DDCB0Q36539474-7FE65973-E85C-431B-9A41-A15AD27A2BEDQ36597491-FA81DC1F-A8E5-4BCE-8F95-251AB6C56460Q36831553-C3D16E0E-51DD-422D-86C3-678119E8C92DQ36831642-4E342F6D-DDD7-4EAE-B583-FC2292747E44Q36924298-4DD3E77F-26AA-4353-8A7D-57EC49D9357FQ37085978-A47CAAB7-0158-43CF-B227-BA817EAC35C0Q37340643-EA5B5405-5404-493F-A736-085B5568F313Q37381494-0FB96820-CD75-4BD3-9C5E-3F977703C919Q37491439-959727E1-EE19-48E0-8092-7A53AF8A6497Q37687679-68CE278B-0A5C-4695-A0B2-C2560FB9D95BQ37702362-A1042185-D2AB-48AD-AC96-330AE61CBC78Q38169761-FE3AF959-950D-403A-B951-F2EEF3DE0C6DQ38199935-0EFDD1A7-AFEA-4072-AA9D-86BC98FC8570Q38228652-B00E3368-5679-47D7-8656-7AFF464573EEQ38264310-95CAA528-374B-4003-8D38-A2A5C87AED0DQ38613648-FB9E15AC-A424-4107-BECF-CD63764FE096Q38675589-F99847D2-A503-45F2-A350-272D9F07AE9BQ38766176-F7ACC5B0-AA21-4C63-8B03-8668AB4E2263Q38769439-CD951157-A5EF-4C5E-954E-0775809852F4Q38784265-67A4BCA9-A394-46E8-B15D-3BAA1B811D03Q38797345-85D41525-8D61-469A-B67C-F7458F448AA1Q38800593-E163F8B2-D8B3-49EE-A4CE-DDF8E7D3FC1EQ39022941-E61D7E1C-90C1-4943-BDFC-87D05563F21CQ39034031-73452719-EDFF-4790-8D15-204926FF364EQ39178065-87121611-B699-4774-A8FF-1D7415E818CCQ39196377-36A614B2-6BE8-48AE-829C-0F1896C045D4Q39242855-59580BB5-EBD5-45AE-9548-54BF1B694B5EQ40219738-74B978B5-2E36-4606-94DA-8DE681970BC2Q42363852-0F2AEF03-B859-46B6-846A-AEB7432B47DC
P2860
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Increase in tumor-associated m ...... ts with recurrent glioblastoma
@en
Increase in tumor-associated m ...... s with recurrent glioblastoma.
@nl
type
label
Increase in tumor-associated m ...... ts with recurrent glioblastoma
@en
Increase in tumor-associated m ...... s with recurrent glioblastoma.
@nl
prefLabel
Increase in tumor-associated m ...... ts with recurrent glioblastoma
@en
Increase in tumor-associated m ...... s with recurrent glioblastoma.
@nl
P2093
P2860
P356
P1433
P1476
Increase in tumor-associated m ...... ts with recurrent glioblastoma
@en
P2093
Anat O Stemmer-Rachamimov
Andrew S Chi
April F Eichler
Christian Davidson
Christine Lu-Emerson
Dan G Duda
Elizabeth R Gerstner
Jennie Taylor
Jermaine Goveia
Jorg Dietrich
P2860
P304
P356
10.1093/NEUONC/NOT082
P577
2013-07-04T00:00:00Z